The mouse model used in this study was IDH1 and IDH2 wild-type, thus our findings revealed that combining gemcitabine with radiation was efficacious in reducing tumor burden and prolonging median survival when compared to radiation or gemcitabine alone in this class of GBM. Here, IDH2 is linked to glioblastoma.